Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin in T2DM Patients with Low vs Normal GLP-1
NCT03659461Completed
- Sponsor
- Universiti Kebangsaan Malaysia
- Start
- Oct 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Universiti Kebangsaan Malaysia. Primary endpoints: Change in blood glucose load response to sitagliptin at 12 weeks and Change in blood insulin response to sitagliptin at 12 weeks. Started Oct 2017; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03659461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03659461.